Cancer Archive — Page 48 of 68
-
September 9, 2016
In search of new cancer targets
Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers. -
September 2, 2016
Kidney cancer educational conference at VICC set Sept. 10
Kidney cancer patients, family members, health care providers and members of the public are invited to attend a free educational workshop about the disease to be held at Vanderbilt-Ingram Cancer Center (VICC). -
September 1, 2016
Lemonade Stand grant boosts Tansey’s pediatric tumor research
William Tansey, Ph.D., professor of Cell Development and Biology and Ingram Professor of Cancer Research, has been awarded a two-year, $250,000 grant from Alex’s Lemonade Stand Foundation (ALSF) to study malignant rhabdoid tumors (MRTs). -
August 26, 2016
New breast cancer driver
Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers. -
August 18, 2016
VICC helps launch new alliance for rare kidney cancer
Children, adolescents or young adults, particularly African-Americans, diagnosed with advanced kidney cancer may actually have a rare form of the disease known as renal medullary carcinoma (RMC) that requires a specialized approach and expert intervention. -
August 17, 2016
Chicken Salad Chick Foundation gift to support Vanderbilt-Ingram Cancer Center research
Chicken Salad Chick Foundation founding board members Stacy Brown and Betty and Earlon McWhorter presented a $200,000 check to Vanderbilt-Ingram Cancer Center (VICC) to support cancer research. Among other initiatives, the Chicken Salad Chick Foundation was proud to host Music and Miracles Superfest, the first major stadium concert in Jordan-Hare’s 75-year history, held on April 23 in Auburn, Alabama. -
August 3, 2016
Kleberg Foundation grant bolsters cancer drug discovery efforts
The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”